TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$165.98 USD
+10.02 (6.42%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $165.96 -0.02 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth C Momentum C VGM
Income Statements
Fiscal Year end for TransMedics Group, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 242 | 93 | 30 | 26 | 24 |
Cost Of Goods | 88 | 28 | 9 | 9 | 10 |
Gross Profit | 154 | 65 | 21 | 17 | 14 |
Selling & Adminstrative & Depr. & Amort Expenses | 183 | 97 | 61 | 43 | 43 |
Income After Depreciation & Amortization | -29 | -31 | -39 | -26 | -30 |
Non-Operating Income | 13 | -1 | -1 | 2 | 0 |
Interest Expense | 11 | 4 | 4 | 4 | 4 |
Pretax Income | -27 | -36 | -44 | -29 | -34 |
Income Taxes | -2 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -36 | -44 | -29 | -34 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -25 | -36 | -44 | -29 | -34 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -28 | -38 | -25 | -28 |
Depreciation & Amortization (Cash Flow) | 8 | 3 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -29 | -31 | -39 | -26 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 32.52 | 29.56 | 27.62 | 24.70 | 14.21 |
Diluted EPS Before Non-Recurring Items | -0.11 | -1.23 | -1.60 | -1.16 | -2.36 |
Diluted Net EPS (GAAP) | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 |
Fiscal Year end for TransMedics Group, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 114.31 | 96.85 | 81.17 | 66.43 | 52.47 |
Cost Of Goods | 45.04 | 36.89 | 33.25 | 25.77 | 15.72 |
Gross Profit | 69.26 | 59.96 | 47.92 | 40.66 | 36.74 |
SG&A, R&D, and Dept/Amort Expenses | 56.76 | 47.54 | 45.32 | 68.99 | 37.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | 12.50 | 12.42 | 2.60 | -28.33 | -0.91 |
Non-Operating Income | 3.27 | 3.57 | 4.87 | 5.00 | 2.43 |
Interest Expense | 3.62 | 3.60 | 3.61 | 3.59 | 2.51 |
Pretax Income | 12.15 | 12.39 | 3.86 | -26.93 | -0.98 |
Income Taxes | -0.04 | 0.20 | -0.17 | -1.51 | 0.02 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 12.19 | 12.20 | 4.03 | -25.42 | -1.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 12.19 | 12.20 | 4.03 | -25.42 | -1.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 35.29 | 34.68 | 34.18 | 32.61 | 32.55 |
Diluted EPS Before Non-Recurring Items | 0.35 | 0.35 | 0.12 | -0.12 | -0.03 |
Diluted Net EPS (GAAP) | 0.35 | 0.35 | 0.12 | -0.78 | -0.03 |